Ultimovacs Overview

  • Founded
  • 2011
Founded
  • Status
  • Public
  • Employees
  • 21
Employees
  • Stock Symbol
  • ULTI
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $8.42
  • (As of Thursday Closing)

Ultimovacs General Information

Description

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
OSL
Primary Office
  • Ullernchausséen 64
  • 0379 Oslo
  • Norway
+47 413 00 000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ultimovacs Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.42 $8.18 $3.70 - $10.66 $270M 32M 23.8K -$0.42

Ultimovacs Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 251,846 251,846 78,800
Revenue 0 0 0 0
EBITDA (12,911) (12,911) (7,313) (6,852)
Net Income (12,740) (12,740) (6,948) (6,788)
Total Assets 62,051 62,051 54,203 21,792
Total Debt 443 443 411 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ultimovacs Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ultimovacs‘s full profile, request access.

Request a free trial

Ultimovacs Executive Team (9)

Name Title Board Seat Contact Info
Carlos de Sousa MD Chief Executive Officer
Hans Eid Chief Financial Officer
Audun Tornes Chief Operating Officer
Sara Mangsbo Ph.D Chief Development Officer
Gustav Gaudernack Chief Scientific Officer
You’re viewing 5 of 9 executive team members. Get the full list »

Ultimovacs Board Members (8)

Name Representing Role Since
00000 00000000 000000 Self Board Member 000 0000
00ø00 00000000 Gjelsten Holding Board Member 000 0000
000000 000ü00000 Gjelsten Holding Board Member 000 0000
00000 000000000 00 Self Board Member 000 0000
00000 0000000000 Self Director 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Ultimovacs Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ultimovacs Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 03-Sep-2018 0000000000 00.000 Drug Discovery 0000 0000000 00.0
To view Ultimovacs’s complete investments history, request access »

Ultimovacs Subsidiaries (1)

Company Name Industry Location Founded
00000000 Drug Discovery Uppsala, Sweden 0000
To view Ultimovacs’s complete subsidiaries history, request access »